BMS, BridgeBio partner to study drug combo for lung cancer July 27, 2021 Auto Bot Clinical Development 0 The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations.
